Últimas noticias sobre ModivCare (NASDAQ:MODV) Bolsa

MODIVCARE INC

ModivCare

ModivCare Inc is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for payors and their members. Its solutions address the social determinants of health (SDoH) by connecting members to essential care services. Its various service offerings include non-emergency medical transportation, personal care, virtual and remote monitoring, consumer health engagement, and integrated supportive care. The company's reportable segments are NEMT, PCS, Monitoring, and Corporate and Other. A majority of its revenue is generated from the NEMT segment, which provides non-emergency medical transportation services.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

MODV

OLMA

Descubre las principales acciones sobrevendidas del sector sanitario con RSI bajo 30, incluyendo SLN, MODV y OLMA.

Las acciones más sobrevendidas del sector sanitario con RSI bajo 30

ModivCare Inc

MELCOR DEV LTD by Melcor Development Ltd.

Melcor Developments Ltd

Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) reported quarterly losses of $(0.14) per share. This is a 99.47 percent increase over losses of $(26.23) per share from the same period last year. The company reported $316.00 thousand in sales this quarter. This is a 15.70K percent increase over sales of $2.00 thousand the same period last year.

Earnings

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Reported May 8, 2025: Faraday Future Q1 EPS $(0.14) Up From $(26.23) YoY, Sales $316.00K Up From $2.00K YoY

Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) has outperformed the market over the past 10 years by 5.35% on an annualized basis producing an average annual return of 15.62%. Currently, Guidewire Software has a market capitalization of $17.91 billion. 
Buying $100 In GWRE: If an investor had bought $100 of GWRE stock 10 years ago, it would be worth $411.90 today based on a price of $213.57 for GWRE at the time of writing.
<h3>Guidewire Software's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746832511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GWRE

$100 Invested In Guidewire Software 10 Years Ago Would Be Worth This Much Today

At 61, many people are daydreaming about what their retirement will look like — morning coffee in the garden, long vacations, or maybe learning how to pickle things just because they can.
Ruth and her husband? They're just hoping retirement is even an option.
"We're wondering if it's too late for us," Ruth told <a href="https://youtu.be/Cnf_QBYvVOc?si=76fDVZPMDJBUpk2q">Dave Ramsey on an episode of The Ramsey Show</a>. She's 61, her husband's 60. And despite earning $130,000 a year, they've only managed to save $75,000 in their 401(k).
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
That's not the only number working against them. They owe $137,000 on their house, another $10,000 on a car loan, and a couple thousand more on credit cards and bills.
Ramsey didn't waste time cutting to the chase. "He makes way too much money for you all to be this broke," he said. Ruth's husband has already accepted his backup plan: work until he drops. Not exactly the dream.
And Ramsey had a pretty bleak — and honestly gross — take on where they were headed. "If you keep spending like you've been spending and stay disorganized like you have been, you're going to retire on dog food," he warned.
That wasn't just a figure of speech. Without major changes, Ruth and her husband could be trading retirement for working forever — or living on whatever's cheapest at the grocery store.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
But it's not hopeless. Ramsey laid out a brutal but doable plan: stop spending, kill the car and credit card debt, build a $15,000 emergency fund, invest 15% of their income, and throw everything else at the mortgage.
"You guys are going to have to get very, very serious today," Ramsey said.
No more vacations. No more eating out — "unless you're working there," Ramsey joked.
It's worth mentioning this call took place back in 2014, when retirement savings benchmarks were much lower. At that time, <a href="https://www.fidelity.com/bin-public/060_www_fidelity_com/documents/18608-02-ExecSum.pdf">Fidelity reported</a> the average 401(k) balance was $91,300. So despite Ramsey's critical take, Ruth and her husband weren't quite the financial disaster he made them out to be. By 2014 standards — and considering wage levels back then — they were actually pretty much on par.
Of course, by today's standards, they'd be trailing badly. <a href="https://newsroom.fidelity.com/pressreleases/fidelity--q4-2024-retirement-analysis--retirement-savers-achieve-positive-momentum-through-2024/s/bbd405d1-c640-4be9-9c7b-67a8fd38e2bb">Fidelity's 2025 report</a> shows the average balance for 60-64 year olds is $246,500.&nbsp;
If they stuck to the plan, Ramsey believed they could retire in seven to nine years with about $500,000 saved and no house payment.
That's a <a href="https://www.benzinga.com/money/smartasset">future worth fighting for</a>. Because the alternative? Dog food.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.</li>
</ul>
Image: Shutterstock

Personal Finance

'Too Late To Retire?' 61-Year-Old Couple Has $75K In 401(k) Despite $130K Salary — Dave Ramsey Warns They'll 'Retire On Dog Food' At This Rate

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $54 to $45.

Price Target

Analyst Ratings

RCKT

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $45

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and lowers the price target from $28 to $25.

FDMT

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

UBS analyst Trung Huynh maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $44 to $38.

CLDX

UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38

Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) has outperformed the market over the past 20 years by 8.79% on an annualized basis producing an average annual return of 16.95%. Currently, Domino's Pizza has a market capitalization of $16.40 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 20 years ago, it would be worth $22,913.88 today based on a price of $478.90 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746829811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Domino's Pizza 20 Years Ago Would Be Worth Today

Social Security is once again a political powder keg — and this time, it's not just politicians stirring the pot.
As fears grow over the program's projected insolvency by 2035, New York University professor and <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45128295/scott-galloway-says-young-men-think-they-can-beat-the-market-urges-30-stock-picks-70-index-funds-and-gamified-budgeting-instead">tech entrepreneur Scott Galloway</a>, known for his sharp and sometimes eyebrow-raising takes, says it's time for a hard reset. And his solution? Cut benefits for seniors who don't actually need the money.
"I believe somewhere between 10% and 30% of people who get Social Security right now should not receive it because they don't need it," Galloway said on a <a href="https://youtu.be/lL91n7QSbjY?si=2uKMz1YPf4wbKopM">November 2023 episode</a> of the "Prof G Show" podcast. "I'll go as high as a third of senior citizens should not be getting Social Security."
Don't Miss:
<ul class="wp-block-list">
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
His argument? Older Americans, as a group, are wealthier than ever. "The wealthiest generation in the history of this planet," as he puts it. Meanwhile, young people face record debt, high housing costs, and wages that haven't kept up.
"The fact that every year we affect a $1.2 trillion transfer from young people, who are not doing as well as they have in past generations, to the <a href="https://www.benzinga.com/personal-finance/24/11/41987495/the-greatest-wealth-transfer-in-history-is-here-but-72-of-americans-say-theyre-not-ready-for-it">wealthiest generation in history</a> means something is wrong," Galloway said.&nbsp;
It's a controversial stance in a country where most seniors rely on those monthly checks. But Galloway's not calling for across-the-board cuts. "I believe that nobody over the age of 65 — or maybe even under 65 — should be living in poverty. I'm absolutely not against cutting Social Security benefits for anyone who needs it."
Instead, he says the system should be means-tested, cutting off wealthier retirees who could live comfortably without Social Security.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
<h2 class="wp-block-heading">Why Now? The Math Doesn't Lie</h2>
Social Security's finances are a mess. Without reform, benefits could be automatically slashed by 17% in just a decade. Part of the problem? When the program started, the average American didn't live long enough to collect decades of benefits. Now, people are living longer, working longer, and the ratio of workers paying into the system to retirees drawing from it has shrunk.
According to the <a href="https://www.ssa.gov/history/ratios.html#:~:text=Covered%20Workers%20is%20defined%20as,status%20as%20of%20June%2030.">Social Security Administration</a>, there were 16.5 workers for every beneficiary in 1950. By 1960, that number had already dropped to 5.1. In 2023, it was just 2.7 workers per beneficiary. The <a href="https://www.ssa.gov/news/press/factsheets/basicfact-alt.pdf">SSA projects</a> that this ratio will continue to decline.&nbsp;
Even Galloway, a self-described capitalist, dismisses the idea that Social Security is just people getting back what they paid in. "The majority of people take out way more than they actually put in," he said.
He also pointed to the payroll tax cap, which limits how much high earners contribute to Social Security. In 2025, <a href="https://www.ssa.gov/faqs/en/questions/KA-02387.html">income above $176,100</a> isn't taxed for Social Security, meaning that individuals earning millions contribute the same dollar amount as someone making $176,100. Galloway argued this kind of imbalance adds to the system's inequities and puts more strain on younger, lower-earning workers.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">The Bigger Debate: Fairness vs. Reality</h2>
Galloway's critics say he's missing the point: Social Security is the most successful anti-poverty program in U.S. history, <a href="https://www.cbpp.org/research/social-security/social-security-lifts-more-people-above-the-poverty-line-than-any-other">cutting senior poverty</a> from around 38% to under 10%.
But Galloway counters that ignoring the math won't help anyone. As he put it, older voters have "figured out how to vote themselves more and more money. It needs to stop." And unless someone tackles the ballooning costs, younger generations will keep footing the bill.
"I think the instinct around reforming Social Security is a good one," he said. "It's something I would like to see someone take it on."
For now, that conversation remains politically toxic. But as the trust fund's expiration date creeps closer, Galloway's blunt proposal may not seem quite so radical in a few years.
Read Next:
<ul class="wp-block-list">
<li>Donald Trump just announced a $500 billion AI infrastructure deal — <a href="https://www.benzinga.com/money/seize-a-share-while-you-still-can-in-the-2-trillion-entertainment-market-with-elf-labs-at-just-2-25-share">here's how you can invest in the entertainment market's next big disruptor at $2.25 per share</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Scott Galloway 'Prof G' Says 30% Of Seniors Should Lose Social Security — Richest Generation Ever Is Taking $1.2 Trillion From Struggling Youth

UBS analyst Christopher Schoell maintains Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy and lowers the price target from $102 to $75.

CCOI

UBS Maintains Buy on Cogent Comms Hldgs, Lowers Price Target to $75

UBS analyst Josh Silverstein maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Buy and lowers the price target from $32 to $30.

CTRA

UBS Maintains Buy on Coterra Energy, Lowers Price Target to $30

UBS analyst Steven Fisher maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Buy and lowers the price target from $154 to $152.

UBS Maintains Buy on Jacobs Solutions, Lowers Price Target to $152

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $110 to $109.

INSM

UBS Maintains Buy on Insmed, Lowers Price Target to $109

UBS analyst Peter Grom maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $63 to $59.

UBS Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $59

UBS analyst Dan Leonard maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $95 to $70.

TECH

UBS Maintains Buy on Bio-Techne, Lowers Price Target to $70

UBS analyst John Lovallo maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Neutral and lowers the price target from $74 to $72.

TREX

UBS Maintains Neutral on Trex Co, Lowers Price Target to $72

UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $27 to $25.

XRAY

UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $25

UBS analyst Kunal Madhukar maintains ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) with a Neutral and lowers the price target from $7 to $6.

UBS Maintains Neutral on ZipRecruiter, Lowers Price Target to $6

UBS analyst Seth Gilbert maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Neutral and lowers the price target from $3.5 to $2.

VERI

UBS Maintains Neutral on Veritone, Lowers Price Target to $2

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) with a Neutral and lowers the price target from $10 to $8.6.

TMCI

UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $8.6

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 12.37%. Currently, UnitedHealth Group has a market capitalization of $344.73 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $3,285.34 today based on a price of $380.02 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746828911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years

Legal

Press Releases

Alert to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Integra LifeSciences Holdings Corporation (NASDAQ: IART); ModivCare, Inc. (NASDAQ: MODV); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office is Investigating Claims on Your Behalf

Alert to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); General Motors Company (NYSE: GM); Integra LifeSciences Holdings Corporation (NASDAQ: IART); and ModivCare, Inc. (NASDAQ: MODV): Act Now as Grabar Law Office Is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Driven Bands Holdings, Inc. (NASDAQ: DRVN); ModivCare, Inc. (NASDAQ: MODV); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Virtu Financial Inc. (NASDAQ: VIRT), Grabar Law Office Investigates Claims on Your Behalf

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf

Modivcare and Aetna Better Health® of Illinois Transform Access to Healthcare in Illinois with Launch of Health Stations

KDK Transport Company Named Modivcare's Virginia Transportation Provider of the Year

Modivcare Announces Changes to Board of Directors

Modivcare to Report First Quarter 2025 Financial Results

Modivcare Announces Executive Leadership Transitions as Part of Strategic Business Model Evolution

Modivcare Reports First Quarter 2025 Financial Results

DRVN

IART

KYTX

MPWR

VIRT

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

DocGo

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Kindly MD

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

National Research Corporation - Common Stock

National Research

Ontrak

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Comments

ModivCare

Noticias

Últimas noticias sobre ModivCare (NASDAQ:MODV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL